激素受体阳性乳腺癌生物标志物与分子诊断新进展
本文综述了激素受体阳性、HER2阴性乳腺癌中与新靶向治疗相关的生物标志物及分子检测应用。涉及CDK4/6抑制剂、免疫检查点抑制剂和PIK3CA抑制剂等治疗场景,从病理学角度探讨耐药相关基因改变的检测与治疗优化。
要点
- 激素受体阳性HER2阴性乳腺癌中CDK4/6抑制剂与免疫检查点抑制剂已用于辅助和新辅助治疗。
- PIK3CA抑制剂用于转移性疾病,需检测PIK3CA基因改变。
- 分子检测可用于识别耐药相关基因改变以优化治疗选择。
核心结论
- 激素受体阳性HER2阴性乳腺癌中新型靶向和免疫治疗的发展为生物标志物分析和分子检测应用创造了机会。
研究设计与样本
- 综述,从病理学角度聚焦与新治疗靶点相关的生物标志物及耐药相关基因改变的分子应用。
主要发现
- CDK4/6抑制剂和免疫检查点抑制剂在辅助和新辅助治疗中应用,PIK3CA抑制剂用于转移性疾病。
- 分子应用可用于识别与耐药或药物相互作用相关的基因改变。
临床怎么用
- 病理科可通过检测与新靶向治疗相关的生物标志物及耐药相关基因改变,辅助选择和优化乳腺癌治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular applications have limited use in breast cancer compared to other cancer types. In recent years, with an improving appreciation of the molecular genetics of breast cancer and innovative novel targeted and immune-mediated therapeutics, opportunities have arisen for more biomarker analysis and molecular applications in the diagnosis and treatment of both locally advanced and metastatic breast cancers. In hormone receptor-positive, HER2-negative breast cancers, a growing number of revolutionized personalized therapies are in clinical use or on trials, such as CDK4/6 inhibitors and immune checkpoint inhibitors in adjuvant and neoadjuvant settings, and PIK3CA inhibitors in metastatic disease. In this review, we focus on biomarkers associated with those new therapeutic targets and molecular applications for genetic alterations associated with drug resistance or interaction from a pathology perspective for selecting and optimizing breast cancer treatment.
引用
- Wang Y, Liu L, Graff SL, et al. Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer. Histopathology. 2024. PMID: 39687977. doi:10.1111/his.15395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。